Latest news
AbCellera Stock Soars 41% After Positive Hot-Flash Trial Data - Briefs FinanceBriefs Finance · Mon, 10 Aug 2026 22:03:09 GMTSilence Therapeutics Jumps Over 25% After Divesiran Phase 2 Trial Supports 12-Week Dosing - TechStock²TechStock² · Mon, 10 Aug 2026 20:28:54 GMTAfter-Hours Top Movers: AbCellera Surges 35% While Bitdeer and Coherent Tumble - Business UpturnBusiness Upturn · Mon, 10 Aug 2026 20:25:00 GMTAbCellera (NASDAQ:ABCL) jumps 37.5% as hot-flash trial hits all main and secondary goals - TechStock²TechStock² · Mon, 10 Aug 2026 18:58:02 GMTAbCellera Jumps 32% After Menopause Drug Slashes Hot Flashes in Phase 2 Trial - finance.biggo.comfinance.biggo.com · Mon, 10 Aug 2026 18:07:00 GMTMidday Movers: AbCellera Surges 32% While Bitdeer and Coherent Slide - Business UpturnBusiness Upturn · Mon, 10 Aug 2026 16:25:00 GMTAbCellera Stock Soars 30% After Menopause Drug ABCL635 Hits Phase 2 Success In Hot Flash Trial Results - International Business Times AustraliaInternational Business Times Australia · Mon, 10 Aug 2026 13:44:13 GMTAbCellera (NASDAQ:ABCL) Shares Surge Ahead of Monday's ABCL635 Phase 2 Trial Results - TechStock²TechStock² · Sat, 08 Aug 2026 14:45:00 GMT